BPG is committed to discovery and dissemination of knowledge
Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 108576
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.108576
Artificial intelligence powered radiomics model for the assessment of colorectal tumor immune microenvironment
Shashank Kumar
Shashank Kumar, Department of Biochemistry, Central University of Punjab, Bathinda 151401, Punjab, India
Author contributions: Kumar S wrote the original draft and conceptualization; reviewing and editing.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shashank Kumar, PhD, Professor, Department of Biochemistry, Central University of Punjab, VPO Ghudda Central University of Punjab Lab no 520, Bathinda 151401, Punjab, India. shashankbiochemau@gmail.com
Received: April 18, 2025
Revised: May 8, 2025
Accepted: June 20, 2025
Published online: November 15, 2025
Processing time: 210 Days and 20.1 Hours
Core Tip

Core Tip: The present hospital-based retrospective research designed an artificial intelligence- and pathological data-based predictive model to make preoperative immunotherapy decisions in colorectal cancer patients. The study includes a small number of individuals from a single medical center. Study claims deep learning radiomics models based on tumor immune microenvironment assessment for personalized immunotherapy decisions in colorectal cancer patients. The study lacks inclusion and exclusion criteria, particularly the exclusion of patients having other malignancies and prior treatment/immunotherapy status. The analysis should look at the clinicopathological features (age, sex, how well the tumor is differentiated, stage, lymph node status, lymphovascular invasion, and perineural invasion) of patients in both the training and validation groups. These metrics will yield valuable insights for therapeutic practice.